Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Afirma Test Gets Coverage From Anthem

NEW YORK (GenomeWeb) – Veracyte said today that Anthem has issued a positive coverage policy for its Afirma gene expression classifier (GEC) for use in thyroid cancer diagnosis.

The genomic test is designed to identify benign thyroid nodules in patients with indeterminate fine needle aspiration biopsy results. With the coverage policy, it is now available to Anthem's approximately 40 million members, Veracyte said.

"Every major health plan in the United States now covers Afirma," Veracyte Chairman and CEO Bonnie Anderson said in a statement. "This is a significant corporate milestone for us as Afirma is one of the only tests in the genomic diagnostics sector to achieve such broad coverage."

Earlier this year, Veracyte announced coverage decisions for the Afirma GEC from 10 Blue Cross Blue Shield plans. According to the company, the test is now covered for more than 260 million individuals, including over 110 million Blues plan members.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.